Literature DB >> 34197952

Serum protein signatures differentiate paediatric autoimmune/inflammatory disorders.

Emil Carlsson1, Angela Midgley1, Simon Perkins2, Eva Caamano-Gutierrez2, Jenna F Gritzfeld1, Michael W Beresford3, Christian M Hedrich4.   

Abstract

Because of their rarity, limited awareness among non-specialists, and significant overlaps in their clinical presentation, childhood autoimmune/inflammatory conditions represent a diagnostic and therapeutic challenge. Juvenile idiopathic arthritis (JIA), with its 7 sub-forms, is the most common paediatric "rheumatic" disease. Juvenile-onset systemic lupus erythematosus (jSLE) is a severe autoimmune/inflammatory disease that can affect any organ system and shares clinical features with JIA. To overcome issues around diagnostic approaches in the context of clinical overlap, we aimed at the definition of disease sub-form specific cytokine and chemokine profiles. Serum samples from patients with JIA (n = 77) and jSLE (n = 48), as well as healthy controls (n = 30), were collected. Samples were analysed using the Meso Scale Discovery (MSD) U-PLEX Biomarker Group 1 (hu) panel. Distinct serum protein signatures associate with JIA vs jSLE disease groups. Proteins with high discriminatory ability include IL-23, MIP-1β, MCP-1, M-CSF and MDC. Furthermore, serum IL-18, MIF, MIP-5 and YKL-40 discriminate between systemic JIA and other JIA subtypes. Thus, simultaneous quantification of serum proteins in a panel format may provide an avenue for the diagnosis and monitoring of childhood autoimmune/inflammatory conditions.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; Childhood; Inflammation; Juvenile; Juvenile idiopathic arthritis; Paediatric; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2021        PMID: 34197952     DOI: 10.1016/j.clim.2021.108790

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  1 in total

Review 1.  Research progress in drug therapy of juvenile idiopathic arthritis.

Authors:  Wen-Jia Zhao; Jiang-Hong Deng; Cai-Feng Li
Journal:  World J Pediatr       Date:  2022-04-01       Impact factor: 2.764

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.